Previous close | 44.57 |
Open | 44.66 |
Bid | 43.66 x 0 |
Ask | 43.67 x 0 |
Day's range | 43.52 - 44.78 |
52-week range | 41.17 - 93.56 |
Volume | |
Avg. volume | 98,495,852 |
Market cap | 123.898B |
Beta (5Y monthly) | 0.68 |
PE ratio (TTM) | 13.48 |
EPS (TTM) | 3.24 |
Earnings date | 29 Jul 2024 - 02 Aug 2024 |
Forward dividend & yield | 0.89 (2.04%) |
Ex-dividend date | 14 Jun 2023 |
1y target est | 75.16 |
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first quarter ending March 31, 2024 ("Reporting Period"):
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the year ending December 31, 2023 ("Reporting Period"):
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.